

BIOTECH VS MICROBES

A Global Snapshot of Microbial Devastation

Health and economies are devastated by pathogens. I2pure is a biotech company fighting, preventing, and curing conditions on the skin.

24 million


By 2030, the estimate of people forced into extreme poverty by antimicrobial resistance

1 Billion

People suffer annually from skin, hair or nail fungal infections

\$644 billion

The annual social impact of biofilms in the USA alone is estimated to exceed \$644 billion^{1,2,3}



Innovator

Through scientific innovation, I2pure has harnessed molecular iodine (I₂) to provide the world a new caliber of iodine.

Defense

When the world was most vulnerable to microbial attack, I2pure embarked on a mission to provide a defense. At its core, I2pure is the convergence of elite scientific advancement and the passion to protect and serve.

Science

Scientific innovation afforded by the esteemed scientist, Dr. Jack Kessler.

<p>1</p> <p>~Iodine~ The gold standard for skin disinfection</p> <p>200 years</p> <p>Molecular iodine is the only biocidal iodine species</p> <p>There are no known pathogens resistant to molecular iodine</p>	<p>2</p> <p>Revolutionizing molecular iodine</p> <p>Freeing</p> <p>Non-irritation and Non-staining</p> <p>With I2pure's innovation, the power of molecular iodine can be delivered in water and emollient bases</p>	<p>3</p> <p>Contextualizing molecular iodine for the first time in medical history</p> <p>Non-Toxic</p> <p>24-hour cytotoxicity trial</p> <p>In a 24-hour in vitro cytotoxicity trial, I2pure's formula was certified non-toxic</p>	<p>4</p> <p>Protection against microbes</p> <p>For All</p> <p>Put the fear of microbes aside</p> <p>I2pure is the new approach to healthy for humans and animals</p>
---	---	---	--



As the threat of microbes increases, impacting global health and economics, you can stand up against viruses, bacteria, and fungi.

I2pure wants to work with you and your community and offers the following options:

- Licensing technology
- Entry into clinical trials
- Bulk sales
- White-label packaging
- Distribution

Fields, M.W., Sturman, P., & Anderson, S. (2020). The establishment of the CBELA UNCHED BIOFILMS as a field of specialized research. *Biofilm*, 2, 100020. doi:10.1016/j.biofilm.2020.100020
Römling, U., Kjelleberg, S., Normark, S., Nyman, L., Uhlin, B.E., & Akerlund, B. (2014). Microbial biofilm formation: A need to act. *Journal of Internal Medicine*, 276(2), 98-110. doi:10.1111/joim.12242
Scharff RL. Economic burden from health losses due to foodborne illness in the United States. *J Food Prot*. 2012;Jan;75(1):23-31. doi:10.4315/0362-028XJFP-11-058. PMID:22221364.

